Kinnate Biopharma
Focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers. Learn more
Launch date
Employees
Market cap
$125m
Enterprise valuation
($26m) (Public information from Apr 2024)
Share price
$2.65 KNTE
San Diego California (HQ)
Authorizing premium user...